Press Room
Let’s Make the Fight Against Kidney Cancer Personal
12/05/2012
AGS-003 is a new type of personalized immunotherapy that is being evaluated in a phase 3 clinical study called ADAPT for the treatment of advanced kidney cancer.
Do you or a loved one have kidney cancer that has spread beyond the kidney?
12/05/2012
Learn how a study using an investigational drug (BNC105P) can be a treatment option for you.
The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma
12/05/2012
Eighty-one patients with 216 BMs were identified. Thirty-seven patients had BM at diagnosis and the remaining 44 were found to have BM at a later point. Forty-one patients never received a TKI and the remaining 40 received TKIs.
We're baking you a very special cookie!
12/04/2012
Greetings of the holiday season from everyone at the Kidney Cancer Association
UK: More flexible drugs system needed
12/04/2012
Before the Affordable Care Act, doctors in the US were on the side of patients, but this does not appear to be true in the UK.
What is the role of nutrition in kidney cancer?
12/03/2012
Can diet help to stave off metastatic disease?
Sequential therapy in metastatic renal cell carcinoma
12/03/2012
Few types of cancer have had their treatment evolve as rapidly as metastatic renal cell carcinoma (mRCC).
A Patient-friendly Summary of the 11th International Kidney Cancer Symposium
12/01/2012
The standard of care for small renal masses has shifted from radical nephrectomy to a strategy to preserve the volume of working kidney as well as the quality of life of the patient. Depending on the size of the tumor and the tissue type (as determined by biopsy), small masses might be watched, or a partial nephrectomy performed to remove the tumor and save as much kidney as possible.
Learn About the ASCO Quality Care Symposium
11/30/2012
Conquer Cancer Foundation of ASCO Honors Researchers for Work in Measuring and Improving the Quality of Cancer Care
FDA Rejection. EU Withdrawal. Set and Match?
11/30/2012
Merck is testing ridaforolimus in other cancer types including kidney cancer.
News Feed| Powered by NeonCRM |